Vanda Pharmaceuticals (NASDAQ:VNDA) CMO Joakim Wijkstrom Sells 30,800 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) CMO Joakim Wijkstrom sold 30,800 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $8.27, for a total transaction of $254,716.00. Following the sale, the chief marketing officer owned 333,469 shares of the company’s stock, valued at $2,757,788.63. The trade was a 8.46% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Vanda Pharmaceuticals Stock Up 4.6%

Shares of NASDAQ:VNDA traded up $0.36 during midday trading on Wednesday, hitting $8.20. The company had a trading volume of 1,262,325 shares, compared to its average volume of 4,505,636. The company has a quick ratio of 2.38, a current ratio of 2.39 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals Inc. has a 12 month low of $3.81 and a 12 month high of $9.60. The firm has a fifty day simple moving average of $7.56 and a 200 day simple moving average of $5.97.

Vanda Pharmaceuticals (NASDAQ:VNDA) last posted its earnings results on Wednesday, February 11th. The biopharmaceutical company reported ($2.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.18) by ($0.21). Vanda Pharmaceuticals had a negative return on equity of 23.85% and a negative net margin of 102.02%.The company had revenue of $57.22 million for the quarter, compared to analyst estimates of $59.28 million. As a group, equities research analysts expect that Vanda Pharmaceuticals Inc. will post -1.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on VNDA. Wall Street Zen lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, February 14th. B. Riley Financial boosted their price target on Vanda Pharmaceuticals from $11.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday, December 31st. Cantor Fitzgerald restated an “overweight” rating on shares of Vanda Pharmaceuticals in a research note on Wednesday, December 17th. UBS Group reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a research note on Monday, January 5th. Finally, Zacks Research lowered shares of Vanda Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 18th. Four analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Vanda Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $14.13.

Hedge Funds Weigh In On Vanda Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. AIGH Capital Management LLC acquired a new stake in shares of Vanda Pharmaceuticals in the fourth quarter valued at approximately $17,626,000. Millennium Management LLC lifted its holdings in Vanda Pharmaceuticals by 220.0% during the 1st quarter. Millennium Management LLC now owns 2,139,591 shares of the biopharmaceutical company’s stock valued at $9,821,000 after purchasing an additional 1,470,898 shares during the last quarter. Jacobs Levy Equity Management Inc. lifted its holdings in Vanda Pharmaceuticals by 552.3% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 708,428 shares of the biopharmaceutical company’s stock valued at $6,248,000 after purchasing an additional 599,818 shares during the last quarter. Marshall Wace LLP boosted its position in Vanda Pharmaceuticals by 945.9% during the second quarter. Marshall Wace LLP now owns 471,720 shares of the biopharmaceutical company’s stock worth $2,227,000 after purchasing an additional 426,620 shares during the period. Finally, Empire Financial Management Company LLC increased its holdings in shares of Vanda Pharmaceuticals by 46.2% in the fourth quarter. Empire Financial Management Company LLC now owns 1,108,245 shares of the biopharmaceutical company’s stock valued at $9,775,000 after purchasing an additional 350,154 shares during the last quarter. Institutional investors and hedge funds own 88.14% of the company’s stock.

Key Vanda Pharmaceuticals News

Here are the key news stories impacting Vanda Pharmaceuticals this week:

• Positive Sentiment: FDA grants a formal evidentiary public hearing for Vanda’s sNDA for HETLIOZ (tasimelteon) in jet lag disorder — described as a landmark action and the first drug approval hearing in over 40 years. This raises the chance for public review and could materially affect approval timing and outcome. PR Newswire
• Positive Sentiment: HC Wainwright maintains a Buy view with a $24 price target and issued updated quarterly EPS forecasts for FY2027 (Q1–Q4 estimates provided). The firm’s constructive outlook and high price target support upside sentiment despite near-term losses. MarketBeat VNDA
• Neutral Sentiment: Technical/volume and valuation context — the stock is trading above its 50-day and 200-day moving averages, market cap is roughly $485M and the company remains loss-making (negative P/E). Current intraday volume is below the 3-month average, which may mute short-term moves. MarketBeat VNDA
• Negative Sentiment: Significant insider selling: CEO Mihael Polymeropoulos, CFO Kevin Moran, CMO Joakim Wijkstrom and two SVPs (Gunther Birznieks and Timothy Williams) each sold large blocks on March 2 (each sale ~30k–156k shares, representing single-digit percentage reductions in their holdings). Multiple high-level executive sales can be perceived negatively by investors and may pressure sentiment even if sales are for diversification or tax reasons. Relevant SEC filings: CEO (Read More.), CFO (Read More.), CMO (Read More.), SVP Gunther Birznieks (Read More.), SVP Timothy Williams (Read More.).

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.